Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04123314 · ClinicalTrials.gov registry record · Early Phase 1
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
A Early Phase 1 study of Depression and Alzheimer Disease, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04123314 is a Early Phase 1 study of Depression and Alzheimer Disease that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 20 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04123314, a Early Phase 1 study of Depression and Alzheimer Disease, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
Maryland
- Johns Hopkins Center for Psychedelic and Consciousness Research - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04123314
The ClinicalTrials.gov registry entry for NCT04123314 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT04123314 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04123314 about?
NCT04123314 is a clinical study titled "Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease". This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quali...
What is the current status of trial NCT04123314?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2021-03-24. Estimated completion is 2026-12-31.
What conditions does trial NCT04123314 study?
This clinical trial studies the following conditions: Depression, Alzheimer Disease, Mild Cognitive Impairment, Depressive Symptoms.
What interventions are being tested in trial NCT04123314?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT04123314?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04123314 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Confirmatory Efficacy Trial of Attention Bias Modification for Depression
RECRUITING · Early Phase 1
-
A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
RECRUITING · Early Phase 1
-
Probiotic Administration for Adolescent Depression
RECRUITING · Early Phase 1
-
Mood Effects of Serotonin Agonists: Depression
RECRUITING · Early Phase 1
-
Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)
ACTIVE NOT RECRUITING · Early Phase 1
-
Testing a Transdiagnostic TMS Treatment Target
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.